Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
US-2024335536-A1 · Oct 10, 2024 · US
Expansion and culture of human-derived natural killer cells by using igfbp2
US2021207097A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021207097-A1 |
| Application number | US-201917059509-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 13, 2019 |
| Priority date | May 31, 2018 |
| Publication date | Jul 8, 2021 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method for the expansion and culture of natural killer cells. By using a method for the expansion and culture of natural killer cells, according to the present invention, the proliferation of human-derived natural killer cells is remarkably enhanced such that natural killer cells to be used for cancer treatment can be efficiently obtained.
First claim
Opening claim text (preview).
1 . A method for culturing of expansion of natural killer cells comprising culturing natural killer cells in a medium containing IGFBP2. 2 . The method of claim 1 , wherein the culturing is performed under a hypoxic condition or a normoxic condition. 3 . The method of claim 1 , wherein the culturing is performed for 1 to 22 days. 4 . The method of claim 2 , wherein the hypoxic condition is a condition of 15 to 0.5% O 2 . 5 . The method of claim 4 , wherein the hypoxic condition is a condition of 5 to 1% O 2 . 6 . The method of claim 2 , wherein the normoxic condition is a condition of 18 to 22% O 2 . 7 . The method of claim 1 , wherein the IGFBP2 is contained at a concentration of 0.1 to 10 μg/ml. 8 . The method of claim 1 , wherein the medium further contains IL-2.
Assignees
Inventors
Classifications
- C12N5/0646Primary
Natural killers cells [NK], NKT cells · CPC title
Antineoplastic agents · CPC title
Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title
Interleukin-2 (IL-2) · CPC title
Insulin-like growth factors [IGF] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2021207097A1 cover?
- The present invention relates to a method for the expansion and culture of natural killer cells. By using a method for the expansion and culture of natural killer cells, according to the present invention, the proliferation of human-derived natural killer cells is remarkably enhanced such that natural killer cells to be used for cancer treatment can be efficiently obtained.
- Who is the assignee on this patent?
- Univ Korea Res & Bus Found
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0646. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jul 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).